IN THE UNITED STATES PATENT AND TRADEMAND OFFICE

The Commissioner of Patents and Trademarks Washington, D.C. 20231



In re application of:	R. Baker, et al.
Serial No.	07/827,187
Filed	1/28/92
Group Art Unit	1203
Examiner	C. Chang

For: IMIDAZOLE, TRIAZOLE, AND TETRAZOLE DERIVATIVES

Sir: →

Transmitted herewith is an amendment in the above-identified application.

☐ No additional fee is required.

The fee has been calculated as shown below.

CLAIMS AS AMENDED

Total Claims Independent Claims Multiple Dependent Claims	(2) Claims remaining after amendment * 18 * 3	-	(4) Highest number previously paid for		(5) Present extra	(6) Rate	(7) Additional fee
			***	10 = 4 = 0	0 x 1 x 0	22 74 230 ••••	=0 =74 =0
	·			FOR TH	ADDITIONAL IIS AMENDME	FEE INT	\$74

- If the entry in Column 2 is less than the entry in Column 4, write "O" in Column 5.
- ** If the "Highest Number Previously Paid For" in this space is less than 20, write "20" in this space.
- *** If the "Highest Number Previously Paid For" in this space is less than 3, write "3" in this space.
- **** Add this fee only if application is amended to include multiple dependent claims (regardless of number) and no multiple dependent claims were originally filed.

Charge \$ 74.00 to Deposit Account No. 13-2755. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2755. Two copies of this sheet are enclosed.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date appearing below.

MERCK & CO. INC.

Date / 21/92

December 21, 1992 IN TRIPLICATE Respectfully

Robert Ø. North

Attorney For Applicant(s)

Reg. No. 27, 366

MERCK & CO., Inc.

Patent Dept. - RY 60-30

P.O. Box 2000

Rahway, N. J. 07065 -0907

(908) 594-7262

IN THE UNITED STATES PATENT AND TRADEMARK FICE

The Commissioner of Patents and Trademarks Washington, D.C. 20231



In re application of:	R. Baker, et al.
Serial No.	07/827,187
Filed	1/28/92
Group Art Unit	1203
Examiner	C. Chang

For: IMIDAZOLE, TRIAZOLE, AND TETRAZOLE DERIVATIVES

Sir:

Transmitted herewith is an amendment in the above-identified application.

- No additional fee is required.
- The fee has been calculated as shown below.

CLAIMS AS AMENDED

(1)	(2) Claims remaining after amendment	(3)	(4) Highest number previously paid for		(5) Present extra	(6) Rate	(7) Additional fee
Total Claims	*18	-	** _	10 =	0 x	22	=0
Independent Claims	*3	-	***		x	.74	=74
Multiple Dependent Claims	0			0	0	230 ****	=0_
		-	•		ADDITIONAL HIS AMENDME		\$74

- * If the entry in Column 2 is less than the entry in Column 4, write "O" in Column 5.
- ** If the "Highest Number Previously Paid For" in this space is less than 20, write "20" in this space.
- *** If the "Highest Number Previously Paid For" in this space is less than 3, write "3" in this space.
- **** Add this fee only if application is amended to include multiple dependent claims (regardless of number) and no multiple dependent claims were originally filed.

Charge $$\frac{74.00}{}$ to Deposit Account No. 13-2755. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2755. Two copies of this sheet are enclosed.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., INC.

December 21, 1992

IN TRIPLICATE

Respectfully,

Robert D. North

Attorney For Applicant(s)

Reg. No. 27,366

MERCK & CO., Inc.

Patent Dept. - RY 60-30

P.O. Box 2000

Rahway, N. J. 07065 -0907

(908) 594-7262

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

90 JAN: 14: -AM: 9: 00

Applicants: R. Baker, et al.

GROUP 120

Serial No.:

07/827,187 (Case No. T-1092Y)

Art Unit:

1203

Filed:

January 28, 1992

Examiner:

Entitled:

IMIDAZOLE, TRIAZOLE AND

TETRAZOLE DERIVATIVES

C. Chang

The Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

STATEMENT UNDER 37 CFR 1.56

Sir:

The following co-pending commonly-assigned application of different inventorship are being brought to the Examiner's attention:

- (1) USSN 07/914,683 (Case T-1070CA), filed July 16, 1992, being a continuation case of USSN 07/641,422 (Case T-1070), filed January 15, 1991, now abandoned, discloses indole substituted five-membered heteroaromatics as 5-HT1 agonists.
- (2) USSN 07/730,751 (Case T-1096IA), filed July 16, 1992, being a continuation in part of USSN 07/665,047, filed March 6, 1991, now abandoned, discloses indazolesubstituted five-membered heteroaromatics as 5-HT1 agonists.
- (3) USSN 07/839,660 (Case T-1098), filed February 20, 1992, describes cyclic sulphonamides as 5-HT₁ agonists.

Respectfully submitted,

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., INC.

Merck & Co., Inc.

Robert J. North

Reg. No. 27,366

P.O. Box 2000 - RY 60-30

Attorney for the Applicants

Rahway, New Jersey 07065-0907

Telephone No. (908) 594-7262

Date: December 16, 1992